Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.

Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.

<h4>Background</h4>This study aims to comprehensively summarize the currently available evidences on the efficacy and safety of gemcitabine plus erlotinib for treating advanced pancreatic cancer.<h4>Methodology/principal findings</h4>PubMed, EMBASE, The Cochrane Library and a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zu-Yao Yang, Jin-Qiu Yuan, Meng-Yang Di, Da-Yong Zheng, Jin-Zhang Chen, Hong Ding, Xin-Yin Wu, Ya-Fang Huang, Chen Mao, Jin-Ling Tang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0057528
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
by: Daniel A Monti, et al.
Published: (2012-01-01)

Identification and validation the predictive biomarkers based on risk-adjusted control chart in gemcitabine with or without erlotinib for pancreatic cancer therapy
by: Aijun Zhao, et al.
Published: (2024-12-01)

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset
by: Makoto Nishio, MD, PhD, et al.
Published: (2025-06-01)

Bufadienolides from Chansu Injection Synergistically Enhances the Antitumor Effect of Erlotinib by Inhibiting the KRAS Pathway in Pancreatic Cancer
by: Yanli Guo, et al.
Published: (2024-12-01)

Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01)

Matters arising: On the cost-effectiveness for the Italian National Health Service of nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic pancreatic cancer
by: Carlo Lazzaro
Published: (2024-12-01)

The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study
by: Kuan-Yu Tseng, et al.
Published: (2025-07-01)

Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
by: Adam R. Wolfe, et al.
Published: (2020-07-01)

Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial
by: Xiao Yang, et al.
Published: (2025-08-01)

Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy
by: M. Sugimori, et al.
Published: (2025-09-01)

A non-inferiority, phase III trial of gemcitabine plus capecitabine gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer
by: Xiaodong Liu, et al.
Published: (2024-12-01)

Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer
by: Geng Xu, et al.
Published: (2025-07-01)

Erlotinib therapy for Olmsted syndrome with p.L655P missense mutation in the TRPV3 gene: a case report
by: Jia Zhang, et al.
Published: (2025-01-01)

WWOX rs11644322 polymorphism, gemcitabine, and pancreatic cancer
by: Sora Yasri, et al.
Published: (2017-01-01)

Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial
by: Jingjing Li, et al.
Published: (2025-07-01)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
by: Jian Wang, et al.
Published: (2020-10-01)

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
by: Xiaofeng Chen, et al.
Published: (2013-01-01)

Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis
by: Jiaqiang Ren, et al.
Published: (2025-04-01)

MLN0905 effectively kills gemcitabine-resistant pancreatic cancer cells by targeting PLK1
by: Min Lin, et al.
Published: (2025-07-01)

Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China
by: Rong Long, et al.
Published: (2025-02-01)

Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancer
by: Eun-Jeong Jeong, et al.
Published: (2025-05-01)

Pathological complete response achieved by gemcitabine plus cisplatin therapy for initially unresectable advanced gallbladder cancer: a case report
by: Yuya Miura, et al.
Published: (2022-01-01)

Visceral Adipose Predicts Prognosis and Toxicities in Locally Advanced Bladder Cancer Patients Treated With Adjuvant Gemcitabine Plus Cisplatin Chemotherapy
by: Zhimin Gao, et al.
Published: (2025-04-01)

Vibrational Fingerprint of Erlotinib: FTIR, RS, and DFT Studies
by: Natalia Piergies, et al.
Published: (2019-01-01)

Erlotinib-Associated Acute Pneumonitis: Report of Two Cases
by: Bobbak Vahid, et al.
Published: (2007-01-01)

Conversion surgery following gemcitabine plus cisplatin therapy for initially unresectable gallbladder cancer with peritoneal carcinomatosis: a case report
by: Yusuke Wakasa, et al.
Published: (2022-03-01)

Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation
by: Yujing Wang, et al.
Published: (2024-12-01)

TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
by: Jia Cao, et al.
Published: (2015-01-01)

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis
by: J. Ventriglia, et al.
Published: (2018-01-01)

Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
by: Chen Y, et al.
Published: (2025-04-01)

Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways
by: Yang Li, et al.
Published: (2025-04-01)

A polymeric nanovesicle delivers sulfopin and gemcitabine to remodel tumor microenvironment for enhanced chemoimmunotherapy against orthotopic pancreatic cancer
by: Weiting Jiang, et al.
Published: (2025-10-01)

TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1‐Mediated Arachidonic Acid Metabolism
by: Xiaona Fan, et al.
Published: (2025-02-01)

Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.
by: Rui Li, et al.
Published: (2013-01-01)

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
by: Wenhua Liang, et al.
Published: (2014-01-01)

ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis
by: Xiaohong Liu, et al.
Published: (2025-08-01)

Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment
by: Xiuping Lai, et al.
Published: (2025-01-01)

Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
by: Wenjie Liu, et al.
Published: (2025-04-01)

Identification of dynamic network biomarker ITGB1 for erlotinib pre-resistance using single-cell differential covariance entropy
by: Xuerong Gu, et al.
Published: (2025-06-01)

An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer
by: REN Jiaqiang, WU Shuai, SU Tong, LI Jie, HAN Liang, WU Zheng
Published: (2024-12-01)